Real-world treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A retrospective chart study

被引：0
|
作者：
Guillaume, Xavier
Horchi, Dahbia
Gomez, Jorge
Hlavacek, Patrick
Ren, Jinma
Schepart, Alex
Aydin, Didem
DiBonaventura, Marco
机构：
[1] Cerner Enviza, Paris, France
[2] Pfizer Inc, New York, NY USA
[3] Pfizer Inc, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18826
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
    Krishnan, Amrita Y.
    Nooka, Ajay K.
    Chari, Ajai
    Garfall, Alfred L.
    Martin, Thomas G.
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Londhe, Anil
    Pei, Lixia
    Eric, Ammann
    Kobos, Rachel
    Smit, Jennifer
    Parekh, Trilok V.
    Slavcev, Mary
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Retrospective study of treatment patterns and clinical outcomes by race in patients with triple-class-exposed multiple myeloma treated in a real-world setting
    Meche, Aster
    Rondeau, Felix
    Gallienne, Samy
    Hlavacek, Patrick
    Ren, Jinma
    Repetny, Karen
    Johnson, Sarasa
    Schepart, Alexander
    DiBonaventura, Marco
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S202 - S202
  • [43] Real-World Treatment Patterns and Outcomes of Triple-Exposed Multiple Myeloma (MM) Patients Treated in Community Oncology Practices in the US
    Smith, Robert
    Xue, Mei
    Dorrow, Natalie
    Varughese, Prateesh
    Hogea, Cosmina
    Buckingham, Trudy
    Sansbury, Leah
    Ferrante, Shannon
    Maiese, Eric M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S419 - S420
  • [44] Treatment preferences among triple-class exposed patients with relapsed/refractory multiple myeloma in the United States (US), United Kingdom (UK), and Germany (DE): a discrete choice experiment
    Rodriguez-Otero, Paula
    Michaels-Igbokwe, Christine
    Collacott, Hannah
    Braverman, Julia
    Marshall, Thomas
    Tinel, Antoine
    Dhanda, Devender
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S209 - S209
  • [45] An indirect comparison of elranatamab's (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM)
    Costa, Luciano J.
    LeBlanc, Thomas William
    Tesch, Hans
    Sonneveld, Pieter
    Kyle, Ryan
    Sinyavskaya, Liliya
    Hlavacek, Patrick
    Meche, Aster
    Ren, Jinma
    Schepart, Alex
    Aydin, Didem
    DiBonaventura, Marco
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study
    Dhanasiri, Sujith
    Hollier-Hann, Georgia
    Stothard, Catherine
    Dhanda, Devender S.
    Davies, Faith E.
    Rodriguez-Otero, Paula
    CLINICAL THERAPEUTICS, 2021, 43 (11) : 1983 - +
  • [47] Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison
    Delforge, Michel
    Anguille, Sebastien
    Depaus, Julien
    Meuleman, Nathalie
    De Velde, Ann Van
    Broek, Isabelle Vande
    Diels, Joris
    Erler-Yates, Nichola
    Van Causenbroeck, Sebastien
    Van Nimwegen, Kirsten
    Vandervennet, Sophie
    Lub, Susanne
    Vekemans, Marie-Christiane Madeleine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S170 - S170
  • [48] Comparative effectiveness of teclistamab versus real-world physician's choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma
    Krishnan, Amrita
    Nooka, Ajay
    Chari, Ajai
    Garfall, Alfred
    Martin, Thomas
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Londhe, Anil
    Pei, Lixia
    Ammann, Eric
    Kobos, Rachel
    Smit, Jennifer
    Parekh, Trilok
    Marshall, Alexander
    Slavcev, Mary
    Usmani, Saad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S174 - S174
  • [49] Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Delforge, Michel
    Kotowsky, Nirali
    Bitetti, Jacopo
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Happ, Lindsey Powers
    Germain, Guillaume
    Urosevic, Ana
    Mahendran, Malena
    Duh, Mei Sheng
    Laliberte, Francois
    Cavo, Michele
    Lee, Hans C.
    HAEMATOLOGICA, 2025, 110 (03) : 753 - 757
  • [50] Real-World Treatment Patterns and Clinical Outcomes Among Triple-Class Exposed and B- Cell Maturation Antigen (BCMA) Exposed Multiple Myeloma Patients
    Mian, Hira
    Harper, Jennifer S.
    Le, Hoa H.
    Fu, Alex Z.
    Patel, Saurabh N.
    Zhang, Xinke
    Fonseca, Rafael
    BLOOD, 2023, 142
12345